Rocuronium Bromide Injection
Product Images NDC 51662-1711

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 51662-1711). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co. Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0143-9250-01 (0143 9250 01 Rocuronium Bromide Injection 50mg Per 5ml (10mgml) 5ml Vial Image)

Label for Rocuronium Bromide Injection 10 mg/mL (50 mg per 5 mL) in a multiple-dose vial. The label includes warnings stating it is a paralyzing agent for intravenous use only. The product is labeled by HF Acquisition Co. LLC, DBA HealthFirst, with dosage and preparation details and a lot and expiration date section. The label also includes a barcode and caution statements in red and black text.*

FDA Label Image

51662-1711-1 (51662 1711 1 Rocuronium Bromide Injection 50mg Per 5ml (10mgml) 5ml Vial Rfid Label Image)

Rocuronium Bromide injection label strip with serialization barcode and regulatory information. The label indicates distribution by HF Acquisition Co., LLC, Mukilteo, WA. The NDC-related numeric codes are visible, along with instructions to see the manufacturer's insert. The label is primarily white with black text and includes a QR code. No strength or dosage form text is visible on the label itself in the image.*

FDA Label Image

Figure (Figure 1)

Two box plot charts illustrating Rocuronium Bromide clinical data. Figure 1 shows time to 80% or greater block versus initial dose by age group (18-64 yrs, 65+ yrs, 1-12 yrs). Figure 2 depicts duration of clinical effect versus initial dose by similar age groups, displaying medians, percentiles, and individual data points in minutes and mg/kg dosing.*

FDA Label Image

Figure (Figure 2)

A line graph titled 'Duration of Clinical Effect vs. Number of Rocuronium Bromide Maintenance Doses, by Dose.' It shows duration in minutes on the vertical axis and dose number on the horizontal axis for two dose groups: 0.15 mg/kg (N=13) and 0.1 mg/kg (N=29). The graph illustrates how duration varies with increasing maintenance doses.*

FDA Label Image

Structure (Structure 1)

Chemical structure of Rocuronium Bromide, showing its steroidal framework with functional groups including an acetate ester (CH3 COO), a hydroxyl group (HO), a quaternary ammonium ion (N+), a vinyl side chain (CH2CH=CH2), and a bromide ion (Br-).*

FDA Label Image

Table (Table 1)

A data table displaying infusion rates using Rocuronium Bromide Injection at a concentration of 0.5 mg/mL. The table shows patient weights in kilograms and pounds and provides corresponding drug delivery rates in micrograms per kilogram per minute, alongside infusion delivery rates in milliliters per hour. The data cover patient weights from 10 kg to 100 kg and drug delivery rates from 4 mcg/kg/min to 16 mcg/kg/min.*

FDA Label Image

Table (Table 10)

A data table titled 'Mean (SD) Pharmacokinetic Parameters in Adults with Normal Renal and Hepatic Function, Renal Transplant Patients, and Hepatic Dysfunction Patients During Isoflurane Anesthesia.' It presents pharmacokinetic parameters including clearance, volume of distribution at steady state, and elimination half-life (t1/2) for three patient groups, with mean values and standard deviations. The table includes a footnote explaining differences in calculated parameters related to study populations and anesthetic techniques.*

FDA Label Image

Table (Table 11)

Data table presenting mean and standard deviation pharmacokinetic parameters of rocuronium in pediatric patients during halothane anesthesia across three age ranges: 3 to <12 months, 1 to <3 years, and 3 to <8 years. Parameters include clearance (L/kg/hr), volume of distribution at steady state (L/kg), and elimination half-life (hours).*

FDA Label Image

Table (Table 12)

Data table presenting mean and standard deviation pharmacokinetic parameters of Rocuronium in pediatric patients during anesthesia with sevoflurane and isoflurane/nitrous oxide. It compares clearance (CL), volume of distribution, and elimination half-life (t1/2) across five age ranges from birth to 17 years.*

FDA Label Image

Table (Table 2)

A data table titled 'Infusion Rates Using Rocuronium Bromide Injection (1 mg/mL)' showing infusion delivery rates in mL/hr based on patient weight in kilograms and pounds, and drug delivery rate in micrograms per kilogram per minute (mcg/kg/min). The table lists infusion rates for patient weights from 10 to 100 kg and drug delivery rates from 4 to 16 mcg/kg/min. A footnote indicates the solution concentration as 100 mg Rocuronium Bromide in 100 mL.*

FDA Label Image

Table (Table 3)

A data table titled "Infusion Rates Using Rocuronium Bromide Injection (5 mg/mL)" showing patient weight in kilograms and pounds, corresponding drug delivery rates in micrograms per kilogram per minute, and associated infusion delivery rates in milliliters per hour. The table illustrates dosing parameters for intravenous administration of Rocuronium Bromide aligned with varying patient weights and infusion rates.*

FDA Label Image

Table (Table 6)

A data table titled 'Percent of Excellent or Good Intubating Conditions and Median (Range) Time to Completion of Intubation in Patients with Intubation Initiated at 60 to 70 Seconds.' It presents rocuronium bromide doses administered over 5 seconds in mg/kg for adults (18-64 years), infants (3 months to 1 year), and pediatric patients (1 to 12 years). The table shows the percent of patients with excellent or good intubating conditions and the median time to completion of intubation in minutes, with dosage groups, sample sizes, and footnotes about exclusions and anesthesia type.*

FDA Label Image

Table (Table 7)

Data table presenting median and range values for time to onset, time to maximum block, and clinical duration of Rocuronium Bromide by dose (mg/kg) administered over 5 seconds. Data is grouped by patient age categories: adults (18-64 years), geriatric (65+ years), infants (3 months to 1 year), and pediatric (1 to 12 years). The table includes notes on patient numbers and clinical duration definitions.*

FDA Label Image

Table (Table 8)

A table presenting median and range times to onset and clinical duration data following the initial intubating dose of Rocuronium Bromide during anesthesia in pediatric patients. It lists doses (mg/kg), time to maximum block (min), and time to reappearance T3 (min) across age groups: neonates, infants, toddlers, children, and adolescents.*

FDA Label Image

Table (Table 9)

A data table titled 'Table 7: Mean (SD) Pharmacokinetic Parameters in Adults (n=22; ages 27 to 58 yrs) and Geriatric (n=20; 65 yrs or greater) During Opioid/Nitrous Oxide/Oxygen Anesthesia.' It presents pharmacokinetic parameters including clearance (L/kg/hr), volume of distribution at steady state (L/kg), and half-life beta elimination (hours) comparing adults aged 27 to 58 years and geriatric patients 65 years or older.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.